Adoport: new tacrolimus brand

Unsupervised switching between different formulations of tacrolimus can lead to graft rejection
Unsupervised switching between different formulations of tacrolimus can lead to graft rejection

Adoport is a new brand of tacrolimus available from Sandoz. The 500 microgram, 1mg and 5mg capsules are indicated for the prevention and treatment of transplant rejection.

As with ciclosporin, the MHRA advises that different brands of tacrolimus are not interchangeable without careful therapeutic monitoring.

View Adoport drug record

Further information: Sandoz

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more